Sagent Pharmaceuticals

Sagent Pharmaceuticals

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $200M

Overview

Sagent Pharmaceuticals, founded in 2006 and headquartered in Schaumburg, Illinois, is a commercial-stage company focused on generic injectable pharmaceuticals. It leverages a global supply network to provide a diverse portfolio of small molecule drugs, with a strong emphasis on packaging innovation to reduce medication errors. The company operates as a private entity, serving the needs of healthcare providers and patients across the United States with a customer-centric business model.

Oncology SupportAnti-infectivesCritical CareAnesthesia

Technology Platform

Proprietary PreventIV Measures® Packaging and Labeling system designed to reduce medication errors, combined with expertise in manufacturing sterile injectables (vials, premix bags, prefilled syringes).

Funding History

4
Total raised:$200M
IPO$75M
Series C$60M
Series B$40M
Series A$25M

Opportunities

The ongoing need for cost-containment in healthcare and frequent shortages of essential injectable drugs create strong demand for reliable generic suppliers.
Sagent's safety-focused packaging provides a key differentiator to secure formulary positions in hospitals concerned with medication error reduction.

Risk Factors

The generic injectables market is subject to severe price competition and rapid erosion.
The company also faces significant regulatory and manufacturing risks associated with sterile production, where any quality issue can lead to recalls and supply disruptions.

Competitive Landscape

Sagent competes with large diversified generic companies (e.g., Pfizer/Hospira, Fresenius Kabi, Hikma) and other pure-play injectable specialists. Competition is based on price, portfolio breadth, supply reliability, and packaging. Sagent's PreventIV Measures® system is a noted point of differentiation in a crowded field.